Audrey Gelot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Audrey Gelot has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Benoit You
Center for Innovation in Cancerology of Lyon (CICLY) EA 3738, Hospices Civils of Lyon, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University Lyon I, 69921, Oullins, France; GINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire), France; GINEGEPS (GINEco Group on Early Phase Studies), France; Hospices Civils de Lyon, Lyon, France
19 shared publications - Gaelle Lescuyer
Center for Innovation in Cancerology of Lyon (CICLY) EA 3738, Hospices Civils of Lyon, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University Lyon I, 69921, Oullins, France; Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, France
19 shared publications - Léa Payen
Institut of Pharmaceutical and Biological Sciences of Lyon, Claude Bernard Lyon I, 69373 Lyon, France
18 shared publications - Christophe Sajous
Department of Oncology, Hospices Civils de Lyon, Lyon, France
17 shared publications - David Dayde
Plateforme de recherche clinique de l‘Institut de Cancérologie des Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon , Pierre-Bénite 69495
17 shared publications - Gilles Freyer
CHU Lyon-Sud, Institut de Cancérologie et Université de Lyon, 69002 Lyon, France
17 shared publications
Latest Publications
- Open Access
- 28 July 2026
- Published by Elsevier in SSRN Electronic Journal
Prognostic value of baseline circulating trimethylated H3K27 nucleosomes in treatment-intent cohorts of non-small cell lung cancer
Background: Information on the value of circulating methylated nucleosomes for predicting prognosis in non-small cell lung cancer (NSCLC) is limited. We sought to evaluate the association between circulating H3K27Me3-concentrations and overall survival (OS) and progression-free survival (PFS).Methods: A retrospective analysis of plasma samples was performed using specimens collected from patients enrolled in the prospective ONCOPRO study (NCT03787056). Patients with NSCLC were classified into 3 cohorts: Curative intent (radiotherapy or surgery) with or without neoadjuvant treatment; Non-Curative first-line treatment including immunotherapy (NC-Imm); and Non-Curative first-line treatment without immunotherapy (NC-NonImm). Plasma H3K27Me3-nucleosome was quantified by an automated chemiluminescent immunoassay (Nu.Q® H3K27Me3).Results: Sixty-four patients were included: Curative, n=19; NC-Imm; n=21; and NC-NonImm, n=24. Median follow-up ranged from 39.5–61.8 months across cohorts. Median baseline H3K27Me3-nucleosome concentrations were 9.54 ng/mL in the Curative cohort, 11.86 ng/mL in the NC-Imm cohort and 27.07 ng/mL in the NC-NonImm cohort (Curative vs NC-NonImm cohort, p=0.0027). In the NC-NonImm cohort, H3K27Me3-nucleosome levels below the median were associated with prolonged OS (hazard ratio [HR][95% confidence intervals] 0.11 [0.01-0.88], p=0.012). Lower H3K27Me3-nucleosome concentrations were also associated with prolonged PFS (HR 0.22 [0.04–1.08]; p=0.043).Conclusion: These findings suggest a potential prognostic value for circulating H3K27Me3-nucleosomes in metastatic NSCLC. Larger studies are warranted to further validate and refine these observations.
- 28 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPrognostic value of baseline circulating trimethylated H3K27 nucleosomes in treatment-intent cohorts of non-small cell lung cancer
Background: Information on the value of circulating methylated nucleosomes for predicting prognosis in non-small cell lung cancer (NSCLC) is limited. We sought to evaluate the association between circulating H3K27Me3-concentrations and overall survival (OS) and progression-free survival (PFS).Methods: A retrospective analysis of plasma samples was performed using specimens collected from patients enrolled in the prospective ONCOPRO study (NCT03787056). Patients with NSCLC were classified into 3 cohorts: Curative intent (radiotherapy or surgery) with or without neoadjuvant treatment; Non-Curative first-line treatment including immunotherapy (NC-Imm); and Non-Curative first-line treatment without immunotherapy (NC-NonImm). Plasma H3K27Me3-nucleosome was quantified by an automated chemiluminescent immunoassay (Nu.Q® H3K27Me3).Results: Sixty-four patients were included: Curative, n=19; NC-Imm; n=21; and NC-NonImm, n=24. Median follow-up ranged from 39.5–61.8 months across cohorts. Median baseline H3K27Me3-nucleosome concentrations were 9.54 ng/mL in the Curative cohort, 11.86 ng/mL in the NC-Imm cohort and 27.07 ng/mL in the NC-NonImm cohort (Curative vs NC-NonImm cohort, p=0.0027). In the NC-NonImm cohort, H3K27Me3-nucleosome levels below the median were associated with prolonged OS (hazard ratio [HR][95% confidence intervals] 0.11 [0.01-0.88], p=0.012). Lower H3K27Me3-nucleosome concentrations were also associated with prolonged PFS (HR 0.22 [0.04–1.08]; p=0.043).Conclusion: These findings suggest a potential prognostic value for circulating H3K27Me3-nucleosomes in metastatic NSCLC. Larger studies are warranted to further validate and refine these observations.
- Open Access
- 10 February 2026
- Published by Elsevier in SSRN Electronic Journal
Prognostic value of baseline circulating methylated nucleosomes in treatment-intent cohorts of non-small cell lung cancer
Background: Information on the value of circulating methylated nucleosomes for predicting prognosis in NSCLC is limited. We sought to evaluate the association of plasma H3K27Me3 and H3K36Me3 nucleosome concentrations with overall survival (OS) and progression-free survival (PFS).Methods: A retrospective analysis of plasma samples was conducted for patients who participated in the prospective ONCOPRO study (NCT03787056). Patients with NSCLC were grouped into 3 cohorts: treated with Curative intent (radiotherapy or surgery) with or without neoadjuvant treatment; Non-Curative first-line treatment including immunotherapy (NC-Imm); and Non-Curative first-line treatment without immunotherapy (NC-NonImm).Results: A total of 64 patients were included: Curative, n=19; NC-Imm; n=21; and NC-NonImm, n=24. Median follow-up ranged from 39.5–61.8 months across cohorts. Median H3K27Me3 nucleosome concentrations at baseline was 9.54 ng/mL in the Curative cohort, 11.86 ng/mL in the NC-Imm cohort and 27.07 ng/mL in the NC-NonImm cohort (Curative vs NC-NonImm cohort, p=0.0027). Median H3K36Me3 nucleosome concentrations were 12.73 ng/mL in the Curative cohort, 12.71 ng/mL in the NC-Imm cohort and 22.62 ng/mL in the NC-NonImm cohort (Curative vs NC-NonImm cohort, p=0.008). In the NC-NonImm cohort, H3K27Me3 or H3K36Me3 nucleosome levels below the median were associated with prolonged OS (hazard ratio [HR][95% confidence intervals] 0.11 [0.01-0.88], p=0.012; HR 0.23 [0.05–1.10], p = 0.045, respectively). In the NC-NonImm cohort, H3K27Me3 below the median was associated with prolonged PFS (HR 0.22 [0.04–1.08]; p=0.043).Conclusion: Our study suggests a prognostic value for circulating methylated nucleosomes in metastatic NSCLC, but larger cohorts are needed to refine and validate this observation.
- 10 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPrognostic value of baseline circulating methylated nucleosomes in treatment-intent cohorts of non-small cell lung cancer
Background: Information on the value of circulating methylated nucleosomes for predicting prognosis in NSCLC is limited. We sought to evaluate the association of plasma H3K27Me3 and H3K36Me3 nucleosome concentrations with overall survival (OS) and progression-free survival (PFS).Methods: A retrospective analysis of plasma samples was conducted for patients who participated in the prospective ONCOPRO study (NCT03787056). Patients with NSCLC were grouped into 3 cohorts: treated with Curative intent (radiotherapy or surgery) with or without neoadjuvant treatment; Non-Curative first-line treatment including immunotherapy (NC-Imm); and Non-Curative first-line treatment without immunotherapy (NC-NonImm).Results: A total of 64 patients were included: Curative, n=19; NC-Imm; n=21; and NC-NonImm, n=24. Median follow-up ranged from 39.5–61.8 months across cohorts. Median H3K27Me3 nucleosome concentrations at baseline was 9.54 ng/mL in the Curative cohort, 11.86 ng/mL in the NC-Imm cohort and 27.07 ng/mL in the NC-NonImm cohort (Curative vs NC-NonImm cohort, p=0.0027). Median H3K36Me3 nucleosome concentrations were 12.73 ng/mL in the Curative cohort, 12.71 ng/mL in the NC-Imm cohort and 22.62 ng/mL in the NC-NonImm cohort (Curative vs NC-NonImm cohort, p=0.008). In the NC-NonImm cohort, H3K27Me3 or H3K36Me3 nucleosome levels below the median were associated with prolonged OS (hazard ratio [HR][95% confidence intervals] 0.11 [0.01-0.88], p=0.012; HR 0.23 [0.05–1.10], p = 0.045, respectively). In the NC-NonImm cohort, H3K27Me3 below the median was associated with prolonged PFS (HR 0.22 [0.04–1.08]; p=0.043).Conclusion: Our study suggests a prognostic value for circulating methylated nucleosomes in metastatic NSCLC, but larger cohorts are needed to refine and validate this observation.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort
Kinetics of peritoneal nucleosomes and CA125
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort
Kinetics of peritoneal nucleosomes and CA125
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Data from Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort
Purpose:Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are expected to be synergistic with intraperitoneal (IP) immunotherapy by increasing tumor antigen expression and mutational load. We assessed the feasibility and safety of IP nivolumab following complete CRS and HIPEC in pretreated patients with recurrent ovarian cancer (ClinicalTrials.gov identifier: NCT03959761).Patients and Methods:Patients received IP nivolumab (0.5, 1, or 3 mg/kg) using a 3 + 3 dose-escalation design, starting 5 to 7 days after CRS and HIPEC. Four IP Q2W (once every 2 weeks) nivolumab infusions were planned. The primary objective was to demonstrate the feasibility of IP nivolumab based on dose-limiting toxicity. Secondary objectives were to assess changes in tolerance of CRS and HIPEC.Results:A total of 17 patients were enrolled including 10 patients in the dose escalation and 7 patients in the expansion phase. No dose-limiting toxicity was observed at any dose level in the 9 evaluable patients. Six of the 17 patients (35%) did not complete all planned infusions: 4 (23.5%) due to peritoneal catheter complications and 2 (11.8%) due to early progression. No procedure-related deaths occurred. Eleven patients (65%) experienced serious adverse events (SAE), mainly transitory grade 3 to 4 transaminase elevations (6/11) and surgery-related (9/11). Four SAEs were related to the peritoneal catheter and two to HIPEC. No SAEs/grade 3 to 4 adverse events related to IP nivolumab occurred.Conclusions:This is the first study demonstrating the feasibility of IP nivolumab in patients with relapsed advanced ovarian cancer. Further investigation at 3 mg/kg is warranted.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort
Purpose:Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are expected to be synergistic with intraperitoneal (IP) immunotherapy by increasing tumor antigen expression and mutational load. We assessed the feasibility and safety of IP nivolumab following complete CRS and HIPEC in pretreated patients with recurrent ovarian cancer (ClinicalTrials.gov identifier: NCT03959761).Patients and Methods:Patients received IP nivolumab (0.5, 1, or 3 mg/kg) using a 3 + 3 dose-escalation design, starting 5 to 7 days after CRS and HIPEC. Four IP Q2W (once every 2 weeks) nivolumab infusions were planned. The primary objective was to demonstrate the feasibility of IP nivolumab based on dose-limiting toxicity. Secondary objectives were to assess changes in tolerance of CRS and HIPEC.Results:A total of 17 patients were enrolled including 10 patients in the dose escalation and 7 patients in the expansion phase. No dose-limiting toxicity was observed at any dose level in the 9 evaluable patients. Six of the 17 patients (35%) did not complete all planned infusions: 4 (23.5%) due to peritoneal catheter complications and 2 (11.8%) due to early progression. No procedure-related deaths occurred. Eleven patients (65%) experienced serious adverse events (SAE), mainly transitory grade 3 to 4 transaminase elevations (6/11) and surgery-related (9/11). Four SAEs were related to the peritoneal catheter and two to HIPEC. No SAEs/grade 3 to 4 adverse events related to IP nivolumab occurred.Conclusions:This is the first study demonstrating the feasibility of IP nivolumab in patients with relapsed advanced ovarian cancer. Further investigation at 3 mg/kg is warranted.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort
Comprehensive protocol of the study
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort
Comprehensive protocol of the study
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort
Representativeness of study participants
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort
Representativeness of study participants
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort
Comprehensive protocol of the study
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort
Comprehensive protocol of the study
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort
Summary of adverse events according to their attributed relationship
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort
Summary of adverse events according to their attributed relationship
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Data from Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort
Purpose:Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are expected to be synergistic with intraperitoneal (IP) immunotherapy by increasing tumor antigen expression and mutational load. We assessed the feasibility and safety of IP nivolumab following complete CRS and HIPEC in pretreated patients with recurrent ovarian cancer (ClinicalTrials.gov identifier: NCT03959761).Patients and Methods:Patients received IP nivolumab (0.5, 1, or 3 mg/kg) using a 3 + 3 dose-escalation design, starting 5 to 7 days after CRS and HIPEC. Four IP Q2W (once every 2 weeks) nivolumab infusions were planned. The primary objective was to demonstrate the feasibility of IP nivolumab based on dose-limiting toxicity. Secondary objectives were to assess changes in tolerance of CRS and HIPEC.Results:A total of 17 patients were enrolled including 10 patients in the dose escalation and 7 patients in the expansion phase. No dose-limiting toxicity was observed at any dose level in the 9 evaluable patients. Six of the 17 patients (35%) did not complete all planned infusions: 4 (23.5%) due to peritoneal catheter complications and 2 (11.8%) due to early progression. No procedure-related deaths occurred. Eleven patients (65%) experienced serious adverse events (SAE), mainly transitory grade 3 to 4 transaminase elevations (6/11) and surgery-related (9/11). Four SAEs were related to the peritoneal catheter and two to HIPEC. No SAEs/grade 3 to 4 adverse events related to IP nivolumab occurred.Conclusions:This is the first study demonstrating the feasibility of IP nivolumab in patients with relapsed advanced ovarian cancer. Further investigation at 3 mg/kg is warranted.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort
Purpose:Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are expected to be synergistic with intraperitoneal (IP) immunotherapy by increasing tumor antigen expression and mutational load. We assessed the feasibility and safety of IP nivolumab following complete CRS and HIPEC in pretreated patients with recurrent ovarian cancer (ClinicalTrials.gov identifier: NCT03959761).Patients and Methods:Patients received IP nivolumab (0.5, 1, or 3 mg/kg) using a 3 + 3 dose-escalation design, starting 5 to 7 days after CRS and HIPEC. Four IP Q2W (once every 2 weeks) nivolumab infusions were planned. The primary objective was to demonstrate the feasibility of IP nivolumab based on dose-limiting toxicity. Secondary objectives were to assess changes in tolerance of CRS and HIPEC.Results:A total of 17 patients were enrolled including 10 patients in the dose escalation and 7 patients in the expansion phase. No dose-limiting toxicity was observed at any dose level in the 9 evaluable patients. Six of the 17 patients (35%) did not complete all planned infusions: 4 (23.5%) due to peritoneal catheter complications and 2 (11.8%) due to early progression. No procedure-related deaths occurred. Eleven patients (65%) experienced serious adverse events (SAE), mainly transitory grade 3 to 4 transaminase elevations (6/11) and surgery-related (9/11). Four SAEs were related to the peritoneal catheter and two to HIPEC. No SAEs/grade 3 to 4 adverse events related to IP nivolumab occurred.Conclusions:This is the first study demonstrating the feasibility of IP nivolumab in patients with relapsed advanced ovarian cancer. Further investigation at 3 mg/kg is warranted.